sur Evotec AG (NASDAQ:EVTCY)
Evotec Receives $2.9 Million Grant for Drug Safety Testing Enhancement
Evotec SE has secured a $2.9 million grant from the Gates Foundation to extend its 2023 initiative on early drug safety assessments using human stem cell technology. The grant supports Evotec’s New Approach Methodologies (NAMs), crucial for predicting the potential developmental risks of new drugs. This three-year extension aims to aid global health researchers in identifying risks to fetal development more effectively.
Dr. Joanna Holbrook, Evotec's Chief Scientific Officer, emphasized the significance of identifying safety concerns early in drug development. The goal is to facilitate informed decisions about drug candidates and mitigate costly changes during clinical testing. The funding acknowledges Evotec's stem cell-based platform, known for its comprehensive human cell data and industrial-scale capability, having screened over 5,000 compounds.
Evotec's efforts align with broader New Approach Methodologies, potentially reducing reliance on animal testing while enhancing research efficiency and predictive decision-making.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Evotec AG